Pluri Inc (PLUR) Stock AnalysisPLURPluri Inc

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Pluri Inc is not a good buy right now due to its declining financial performance and negative momentum indicators. The current price is $1.53, which is significantly lower than its 200-day simple moving average of $2.88, indicating a bearish trend. Additionally, the RSI is at 39.19, suggesting that the stock is nearing oversold territory, but it has not yet reversed. The company has also reported a staggering year-to-date change of -48.83% and a one-year change of -69.10%, reflecting ongoing struggles. The main risk is the negative net income, which reached -6,172,000 in Q3 2026, indicating persistent losses that could deter potential investors.